Join our daily newsletter At The Bell to receive exclusive market insights
- Healthia (HLA) says its earnings could double compared to the same period last year in its upcoming interim financial report
- The company expects to land between $10.7 million and $11.7 million in earnings over FY21’s first half — indicating a jump of between 86 and 103 per cent
- The healthcare stock’s revenue is also projected to rise — the upper end of its guidance represents a 44 per cent increase on 1H FY20’s $44.26 million result
- While today’s projections are unaudited, it hasn’t stopped investors from sending Healthia’s share price into the green
- The company closed Tuesday’s session up 4.65 per cent, trading at $1.80 per share
Healthia (HLA) says its earnings could double compared to the same period last year in its upcoming interim financial report.
In its latest round of unaudited financial guidance, the healthcare stock advised its underlying earnings before interest, taxes, depreciation and amortisation (EBITDA) could jump between 86 and 103 per cent on the previous corresponding period (pcp).
That means the company expects to land between $10.7 million and $11.7 million in earnings over FY21’s first half.
Healthia’s revenue guidance is also up on the pcp. It’s forecast to net between $62 million and $64 million — at best, a 44.6 per cent increase on 1H FY20’s $44.26 million result.
Following the robust growth, Healthia believes its underlying earnings per share (EPS) will also spike. At the top end of its guidance, the company forecasts its EPS will hit 7.24 cents — nearly double the 3.85 cents per share recorded this time last year.
Managing Director Wesley Coote chalked the promising guidance up to Healthia’s “strong organic growth” and a suite of strategic acquisitions.
In December last year, the company bought specialist footwear retailer Natural Fit Footwear for $2.7 million. But Healthia’s biggest acquisition for 2020 came in late October when it secured The Optical Company (TOC) for $43 million.
In FY20, TOC tabled $128.3 million in underlying revenue, $18.9 million in underlying EBITDA and $7.5 million in underlying net profit after tax.
While today’s projections are unaudited, it hasn’t stopped investors from sending Healthia’s share price into the green.
The company closed Tuesday’s session up 4.65 per cent, trading at $1.80 per share. Since January 1, Healthia has added over 50 cents to its share price.
